Bernward Garthoff – författare

At the Pharmacology Workshop held in Wuppertal on December 11, 1992, Dr. Alexander Scriabine was honored for his contribution to drug develop- ment at our company. Dr. Scriabine was the first pharmacologist to join Miles in West Haven, CT, in 1979. He established the Miles Institute for Preclinical Pharmacology, at the Yale campus, which was devoted to cardiovascular, metabolic and, 2 later, CNS research. At that time Ca + antagonists were not yet available in the USA, but well established in Europe. At Bayer, Bossert and Vater discovered 1,4-dihydropyridines in the late 1960s, and Fleckenstein identified 2 nifedipine as the most potent Ca + antagonist available at that time. This 2 discovery led to the establishment of Ca + antagonists as leading cardio- vascular drugs throughout the world and to the marketing of nifedipine as Adalat by Bayer. The main function of the Miles Institute for Preclinical 2 Pharmacology was the introduction of Bayer Ca + antagonists to the American scientific community.Scriabine, in collaboration with Stanislav Kazda and Bernward Garthoff, contributed numerous publications on the 2 pharmacology of Bayer Ca + antagonists, supported many collaborative studies with extramural investigators in the USA, and organized several 2 international conferences on Ca + antagonists. These conferences contri- buted to the recognition of the importance of these drugs for the treatment of hypertension and coronary heart disease in North America.

At the workshop held in Leverkusen on December 1, 1993, Professor Dr. Stanislav Kazda was honored on the occasion of his retirement for his scientific contributions and his involvement in drug development in our company, Bayer AG. In a recent article by Eugene Garfield (Current ContentslLife Sciences 36:3-15, 1993), what most of us participating in this workshop have supposed for years was confirmed: that Kazda is one of the leading scientific authors in academia worldwide. In the said survey of citations of biomedical research articles, Kazda is number 29 in terms of actual impact, individual ~itations, and total number of published manuscripts (and this only covers the time period from 1981 to 1992). In addition, his work has contributed significantly to the number eight ranking of our company in the so-called Corporation List. With the support of colleagues inside and outside the company, Kazda made a new substance class, the 1, 4-dihydropyridines, discovered by Bossert and Vater, well known to the scientific community on a worldwide basis and established its outstanding usefulness in hypertension. He has contributed numerous publi­ cations on the pharmacology of these calcium antagonists and organized several international conferences on the topic. Although he became famous as a cardiovascular pharmacologist, he started his career as a physician with the subjects obstetrics and gynecology. He studied at the Medical Faculty in Prague and at the Universities of Kasan and Kharkow (1950-1957).

At the workshop held in Leverkusen on December 1, 1993, Professor Dr. Stanislav Kazda was honored on the occasion of his retirement for his scientific contributions and his involvement in drug development in our company, Bayer AG. In a recent article by Eugene Garfield (Current ContentslLife Sciences 36:3-15, 1993), what most of us participating in this workshop have supposed for years was confirmed: that Kazda is one of the leading scientific authors in academia worldwide. In the said survey of citations of biomedical research articles, Kazda is number 29 in terms of actual impact, individual ~itations, and total number of published manuscripts (and this only covers the time period from 1981 to 1992). In addition, his work has contributed significantly to the number eight ranking of our company in the so-called Corporation List. With the support of colleagues inside and outside the company, Kazda made a new substance class, the 1, 4-dihydropyridines, discovered by Bossert and Vater, well known to the scientific community on a worldwide basis and established its outstanding usefulness in hypertension. He has contributed numerous publi­ cations on the pharmacology of these calcium antagonists and organized several international conferences on the topic. Although he became famous as a cardiovascular pharmacologist, he started his career as a physician with the subjects obstetrics and gynecology. He studied at the Medical Faculty in Prague and at the Universities of Kasan and Kharkow (1950-1957).